Article Per Year (5 Year)
p-Index From 2020 - 2025
0
P-Index
This Author published in this journals
All Journal Indonesian Journal of Clinical Pathology and Medical Laboratory (IJCPML)
I Nyoman G Sudana
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Medicine & Pharmacology Neuroscience

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
PERBEDAAN BERMAKNA KADAR SERUM AMILOID A ANTARA STENOSIS KORONER DIBANDINGKAN BUKAN STENOSIS KORONER (Significantly Higher Level of Serum Amyloid A Among Coronary Stenosis Compared to NonStenosis) I Nyoman G Sudana; Setyawati Setyawati; Usi Sukorini
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 21, No 3 (2015)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v21i3.1273

Abstract

Coronary stenosis is one of the major causes of death from heart disease. The gold standard of coronary stenosis diagnosis isestablished with angiography, however it is invasively, complicated and expensive. Serum Amyloid A (SAA) is an acute phase proteinthat appears as chronic and acute inflammatory agent that is specific to the process of stenosis development. Serum Amyloidal A testmethod is noninvasive, relatively easy and affordable. The aim of this study was to know the differences of Serum Amyloid A levelsin patients with nonstenosis and coronary stenosis in Dr. Sardjito General Hospital Yogyakarta by determination. The study is a casecontrol study. The samples were selected consecutively with typical chest pain, were divided into two (2) groups of nonstenosis andstenosis by coronary angiography test. The principal of the Serum Amyloid A test is ELISA method. Nonstenosis and coronary stenosisgroups were analyzed by mean of Serum Amyloid A level based on the angiography test. The data were analyzed with Independentt-test, odds ratio with a significancy of p <0.05 and confidence interval 95%. The samples of this study consisted of 60 patients, dividedinto nonstenosis and coronary stenosis. The analysis of Independent t tests showed significant differences between the subject SAA levelsof nonstenosis and stenosis (4.35 ug/mL vs 21.75 mg/mL, p=0.001, with an odds ratio 9.84 (CI 95% 2.38 to 40.73). Based on thisstudy, it can be conclued that the results indicate significantly higher level of Amyloid A Serum among the coronary stenosis comparedto the nonstenosis.
HEART FATTY ACID BINDING PROTEIN SEBAGAI PETANDA BIOLOGIS DIAGNOSIS SINDROM KORONER AKUT Ira Puspitawati; I Nyoman G Sudana; Setyawati Setyawati; Usi Sukorini
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 22, No 2 (2016)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v22i2.1114

Abstract

Heart-Fatty Acid-Binding Protein (H-FABP) is a membrane-bound protein that facilitates transport of fatty acids from the blood intothe heart. It is a low molecular weight cytoplasmic protein. Because of its small size and location, it is released rapidly into the bloodfollowing myocardial damage. The H-FABP levels rise as early as between 1−3 hours after the onset of Acute Coronary Syndrome, thepeak situation between 6−-8 hours, and returns to normal within 24 hours. The purpose of this study was to know the cut-off value ofHeart Fatty Acid Binding Protein with a sensitivity of at least 90% in patients with acute coronary syndrome in the Dr. Sardjito HospitalYogyakarta. The researchers undertook a cross sectional evaluation of 75 consecutive patients admitted with acute chest pain suggestiveof acute coronary syndrome (ACS). The H-FABP was measured by using immunoturbidimetry assay methods. The receiver operatingcharacteristic (ROC) analysis was calculated for the cut off point, sensitivity and specificity estimation. A total of 75 patients (59 in theACS group and 16 in the control group) were included in this study, and the majority of the ACS group (64 [76.2%]) were male patientswith AMI, 20 (26.7%) had an ST-elevation myocardial infarction and the rest (21 [28%]) had a non–ST-elevation myocardial infarction.The optimized cut-off obtained for h-FABP was 15 ng/mL, showing a sensitivity and specificity of the H-FABP assay for detecting ACSas 98.31 (95% CI 90 to 100) and 93.75% (95% CI 86 to 99), respectively. The areas under the receiver operator characteristic (ROC)curves to distinguish ACS from non-ACS were 0.983 (95% CI: 0.927– 0.999) for H-FABP. The optimized cut-off obtained for H-FABPwas 15 ng/mL, showing a 98.31% sensitivity and 93.75% specificity for detecting ACS in the Dr. Sardjito Hospital Yogyakarta.
Co-Authors Ira Puspitawati Setyawati Setyawati Usi Sukorini